Outcome of Board Meeting held on 14th October, 2026

BACIL PHARMA LIMITED Reg Office: G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai - 400099 Email Id: bacilpharma07 @gmail.com, CIN: L24200MH1987PLC043427, Tel: 22618452/22661541, Tel/Fax: 22618327 Date: October 14, 2026 The Manager, Listing Department, BSE Limited P.]. Towers, Dalal Street, Mumbai - 400001 Scrip Code: 524516 Sub: Outcome of the Board Meeting held on Wednesday, October 14, 2026 Ref: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we wish to inform you that the Meeting of the Board of Directors of Bacil Pharma Limited was held on Wednesday, October 14, 2026 at the Registered Office of the Company, wherein the Board has, inter alia, considered and approved the following: 1. Approved the Unaudited Financial Results of the Company for the half year and quarter ended September 30, 2026, along with the Limited Review Report issued by the Statutory Auditors of the Company. The meeting of the Board of Directors commenced at 03:00P.M. and concluded at 04:00 P.M. The Unaudited Financial Results and Limited Review Report will be submitted separately in the prescribed format as per SEBI LODR Regulations. Kindly take the above on your record and acknowledge the receipt. Thanking you, For Bacil Pharma Limited Chaitali Kalpataru Shah Director & CFO Din: 11167778 BACIL PHARMA LIMITED {CIN : L24200MH1987PLC043427} Unaudited Financial Results on Standalone basis for the Quarter and Half Yearl Ended 30th September, 2026 Prepared In Compliance with the Indian Accounting Standards (IND AS) @ inLakko) Quarter Ended Half Year Ended Year ended oy Particulars 30-09-2026 30062026 30-09-2026 30092025 31032026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Audited 1 [Revemue from operations [Other income 918} 891 1809) 10574 12352 [Total revenue 918 851 1809 10574 12352 2 [Expenses Cost of material consumed , i i [Purchases of Stock in frade , i i [Employee benefits expense on on L4 358 48 [Finance Cost , i i IDeprecation and amortization expense , i i [Other expenses s 15 636) 1056} 1961 [T otal expenses 593 227 820 1454 2450 [Profit/ (Loss) from ordinary activities before tax 338 664 989 9120 9.0 3 |Tax expense: (Current tax o o o 9 - IDeferred tax 43 825 1248 2295 5653 4 [Profit/(Loss) from ordinary activities after tax () [ .59 625 155.55 5 |other Comprehensive Income (0CD Item that will not be reclassified to profit o loss |G ain/(Loss) on recogniseodn fair valuaion of Financial Assets 16.27) 173 1301 669 )| Income tax relating to theseitems o o 082 - [Total Other Comprehensive Income (OCD 1627 am 4801 587 @) [Profit/(Loss) for the Period 1529 0z 542 1 ©189) [Paid up Equity Share Cap(iFacte aVallue of Rs. 10 each) 1397.08 1,397.08 139703 1397.03 1397.03 6 [Earing Per Share (EPS ) (Not annualised) (1) Basic o 0 03 053 1 | Dillted o 022 03 053 1 Seenotesaccompanying to the Financial statements Notes: 1 [The aforesaid unaudited financial results have been reviewed and recommended by Audit Committee and approved by the Booaf Dirrectdors at their meeting held on 14-10-2026 [ Te Statutory Aucitors of the Company have.caried out » ‘Limited Review” of the sbove results a5 per regutions 33 of SBI (Lstng Obigations and Disclosures Requirement)| Regulations, 2015, 3 | The figures for the Quarter/ half Year ended 30th September, 2026 are in compliance with the Indian Accounting Standards(ing AS) notified by the Ministry of Corporate Affars [The Financial resuits have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 Interim Financial reporting, 4 [notified under section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time, and other accounting principles generaly accepted i India. 5 [Theformafotr above resuits as prescried in SEBIs circular CIR/CFD/CMD/15/2015 dated Nov 30, 2015 has been modietdo comply with the requirements of SEBI's circular Gated| 1y 5, 2016, Ing 45 and Schedule Il [Divi1s] ito othne CompaniAects, 2013 applitoc caombpalniees that are requtio rcoempdly with Ind As, 6 [The Companhays only one reportable primary pharmbusainecss seegmuenttas pier cINDa AS l108 7 |Figures for the previous period have been regrouped, reclassified and restated wherever necessary to make them comparable with the current periods fiures. |A s per our report of even date attached. For Bacil Pharma Limited Ms Chaitali Kalpataru Shah Direc&t CoFrO DIN: 11167778 piace : Mumbai [Date : 14-10-2026 BACIL PHARMA LIMITED CIN :L24200MH1987PL C043427 Regd. Off.: G2 & G3, Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai 400099 Email: bacilpha@yahoo.com Standalone Balance Sheet as at 30th September,2026 (Rupees in Lacs) As at 30th As at 31st Paarrttiiccuull ars NoOtte NoN0. | September,2026 | March,2026 1. ASSETS 1 Non-current assets Property Plant and Equipment 3 0.00 0.00 Assets Classified as held for sale Property Plant and Equipments 0.00 0.00 Financial Assets (a) Investments a4 2235 2424 (b) Loans 5 104.77 78.10 Deferred tax assets (net) 6 49.41 61.89 2 Current assets Financial Assets (a) Investments - (b) Trade receivables 110.89 118.00 (c) Cash and cash equivalents 7 3031 56.85 Other current assets 8 3.80 0.45 Total 2534.21 2739.26 Il. EQUITY AND LIABILITIES 1 Equity Equity Share capital 9 1397.02 1397.02 Other Equity 10 1130.19 1084.24 2 Non-current liabilities Financial Liabilities Deferred tax liabilities 3 Current lia Financial Liabilities (a) Borrowings 11 0.00 0.00 (b) Trade Payables 12 Total outstanding due of (A) Micro enterprises and small enterprises (B) Creditors other than micro enterprises and 6.99 1.97 small enterprises ( c) Other Financial Liabilities 0.00 18.00 Other current liabilities 13 0.00 0.00 Provisions 14 0.00 238.06 Total 2534.21 2739.26 Summary of Significant Accounting Policies See Other notes to Accounts For and on behalf of the Board| BACIL PHARMA LIMITED Ms Chaitali Kalpataru Shah Director & CFO DIN : 11167778 Place : Mumbai Date: 14/10/2026 BACIL PHARMA LIMITED STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 30th Sep, 2026 (Amount in LAKH) N Year ended Year ended Particulars 30.09.2026 31.03.2026 [A. CASH FLOW FROM OPERATING ACTIVITIES Net (Loss) /profit before tax 9.89 99.02 Adjustments for Depreciation 0 0 Loss on sale of Fixed Asset 0 0 Increase in DTA [ -56.53 Interest & Dividend Income [ [ Operating profit before working capital changes 9.89 42.49 (Working Capital adjustments :- Increase/(Decrease) in Trade and Other Payables 5.03 1.55 Increase/(Decrease) in Borrowings 0.00 -11.22 Increase/(Decrease) in Provisions -238.06 238.06 Increase/(Decrease) in Other Financial Liabilities -18.00 14.1 Increase/(Decrease) in Other Current Liabilities 0.00 -0.09 (Increase)/Decrease in Trade Receivable 7.11 -118.00 (Increase)/Decrease in Deferred tax assets 12.48 0.00 (Increase)/Decrease in Other Current Assets. -3.35 457 Cash generated from /(used in) operations -224.89 171.46 Direct taxes paid (Net of Refunds) Net cash (used in)/ from generated from operating activities -224.89 171.46 B. CASH FLOW FROM INVESTING ACTIVITIES Purchase of Property, Plant & Equipment 0 0 Proceeds Purchase/Sale of Investments o o Interest & Dividend Income [ [ (Increase)/Decrease in Investment 189 -288.31 (Increase)/Decrease in loans -26.67 -50.15 Net cash (used in)/ from generated from investing activities 162.28 -338.47 C. CASH FLOW FROM FINANCING ACTIVITIES Increase/(Decrease) of Unsecured Loan (1] (1] Proceeds from Preferential Allotment of Shares 0 0 Increase/(Decrease) of other equity 36.08 -61.88 Net cash (used in)/ from generated from financing activities 36.08 -61.88 D. Net Increase/Decrease in cash and cash equivalents (A+B+C) -26.53 -22 [Showing first 8,000 characters — download PDF for full document]